Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares Core MSCI Emerging Markets ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while iShares Core MSCI Emerging Markets ETF trades at $77.27 (market cap $154.46B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 55× Dyne Therapeutics Inc. Common Stock's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares Core MSCI Emerging Markets ETF for 59 Days on average.
| DYN | IEMG | |
|---|---|---|
Market Cap | $2.81B | $154.46B |
Volume | 2,195,902 | 11,412,044 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $86.00 |
52-Week Low | $14.60 | $64.72 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
IEMG trades at $80.22, down 0.51% with a bearish technical signal. The ETF faces selling pressure below key resistance at $81-$82. Emerging markets exposure offers growth potential but carries higher volatility than developed markets. Recent news highlights IEMG's strong performance versus peers like SCHE and VWO, with 35% trailing returns.
The outlook balances emerging markets growth against macroeconomic risks. IEMG's technology sector concentration (39%) provides upside from AI trends but increases sensitivity to sector volatility. Expense ratio competitiveness remains key versus lower-cost alternatives like SCHF at 0.03%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
